Glanbia 13% surge as it eyes €400m deals

Shares in foods giant Glanbia surged 13% as it eyes €400m in further acquisitions on the back of better than anticipated results for 2018.

Glanbia 13% surge as it eyes €400m deals

Shares in foods giant Glanbia surged 13% as it eyes €400m in further acquisitions on the back of better than anticipated results for 2018.

Chief executive Siobhán Talbot said the firm, whose value soared €700m to over €5.4bn, would look for further acquisitions in the US and other regions. It announced its another US deal, buying non-dairy ingredients firm Watsons for €78.5m.

Earnings before interest, tax and, amortisation, or Ebita, grew 5.2% to around €285m as revenues increased by over 4% to €2.39bn. Earnings per share rose 9%, beating guidance.

Ms Talbot said Glanbia would seek out more acquisitions, based on more joint-ventures for its dairy-focused operations and full buyouts involving its nutrition and sports foods divisions.

Glanbia's €308.5m purchase of SlimFast last year saw the brand post 18% growth in 2018.

"We’re participating with our partners on some very big spends, probably €1bn, within that primary dairy. So when we move from dairy to the wholly-owned businesses of Glanbia Nutritionals and Glanbia Performance Nutrition, it is not unfair at all to say the focus there is on full acquisitions," she said.

Cash numbers were "very good", Ms Talbot said, which gives Glanbia "a good bandwidth to continue to invest".

I would say we are probably looking at €300m to €400m. When it comes to geography, we’re pretty neutral on it. It is probably coincidental that recent opportunities have come up in North America, where we already have a good footprint. If there are opportunities for businesses in other regions that are complementary, we would be very open to that also.

"We would be very keen to continue to acquire.

"We set out our ambition to take the group to €6bn by 2022. In recent years, Glanbia has been very much that blend of acquisition-fuelled growth, and organic growth," she said.

Sports and health and so-called wellness nutrition would continue to fuel growth, according to Ms Talbot.

SlimFast, Optimum Nutrition, BSN and Body & Fit were moving from niche markets into the mainstream, she said.

"We’ve become even clearer ourselves strategically on where those brands will play - the total spectrum historically around sports performance, right through to men and women who are just thinking of their health," she said.

Brokers hailed the results.

Goodbody said it had outperformed in the fourth quarter, while Davy said "the results attest to the strength of Glanbia’s growth algorithm".

more courts articles

DUP calls for measures to prevent Northern Ireland from becoming 'magnet' for asylum seekers DUP calls for measures to prevent Northern Ireland from becoming 'magnet' for asylum seekers
UK's Illegal Migration Act should be disapplied in Northern Ireland, judge rules UK's Illegal Migration Act should be disapplied in Northern Ireland, judge rules
Former prisoner given indefinite hospital order for killing Irishman in London Former prisoner given indefinite hospital order for killing Irishman in London

More in this section

Currys' financials Currys shares jump on trading update a month after retailer rejected unwanted takeover offer
Joe Biden Biden increases tariffs on Chinese imports of electric cars and chips
Construction - digger working at building site on sunny day Large investment funds eye office and data centre projects now interest rates are about to turn
IE logo
Devices


UNLIMITED ACCESS TO THE IRISH EXAMINER FOR TEAMS AND ORGANISATIONS
FIND OUT MORE

The Business Hub
Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Sign up
ie logo
Puzzles Logo

Play digital puzzles like crosswords, sudoku and a variety of word games including the popular Word Wheel

Lunchtime News
Newsletter

Keep up with the stories of the day with our lunchtime news wrap.

Sign up
Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited